Navigation Links
ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc.
Date:2/14/2011

es of common stock upon successful achievement of development milestones consisting of dosing the first patient in a phase 3 clinical study, acceptance by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) and approval by the FDA of an NDA.  If all milestones are achieved without reduction, the number of shares issued in connection with the acquisition would, in the aggregate, represent an approximately 40% ownership stake in ADVENTRX (based on currently outstanding shares plus shares issued in connection with the acquisition). Of the total number of shares issuable, more than 75% are based on NDA acceptance and approval.

If ADVENTRX's stockholders do not approve the issuance of the milestone-related shares as required by NYSE Amex listing standards, ADVENTRX expects to pay SynthRx's stakeholders in cash the value of the shares it otherwise would have issued, with the NDA acceptance and NDA approval milestone payments payable based on net sales of 188 and all milestone payments payable in quarterly installments.

About Poloxamer 188

Poloxamer 188 is a nonionic block copolymer surfactant that is believed to adhere to hydrophobic surfaces that develop when cells are damaged. It has been shown to restore hydration lattices and minimize the cascade of adhesive, inflammatory and coagulation responses that cause adhesion of cells, impaired blood flow and tissue ischemia. Improving blood flow in the microvasculature may benefit patients with sickle cell disease in acute crisis, which is associated with microvascular occlusion. Formulations of 188 have been extensively studied in numerous clinical trials, including a 2,950-patient, randomized, controlled study in acute myocardial infarction.  

SynthRx's lead product candidate, a purified form of poloxamer 188, is an investigational product intended to treat micro-vascular disorders. Purified poloxamer 188 has been evaluated in multiple clinical st
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ADVENTRX to Provide Update Regarding Pipeline Expansion Efforts
2. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15
3. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
4. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
5. ADVENTRX Pharmaceuticals Announces Capital Raise of $22.5 Million
6. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
7. ADVENTRX Pharmaceuticals to Present at the 4TH Annual OneMedForum Business Development and Investment Conference on January 11
8. ADVENTRX Requests Meeting with FDA to Discuss ANX-514 Study
9. ADVENTRX Reports Third Quarter Financial Results
10. ADVENTRX to Present at the Wall Street Analyst Forum 21st Annual Institutional Investor Conference on November 11
11. ADVENTRX Submits Exelbine™ New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Mass. , Sept. 17, 2014 /PRNewswire/ ... disease/ulcerative colitis (CD/UC) patients eligible for biologic ... receive a biologic. Surveyed gastroenterologists cite patients, ... reason for low penetration rates, followed by ... and UC patients receiving biologics, Janssen Biotech,s ...
(Date:9/17/2014)... MARINA DEL REY, Calif. , Sept. 17, ... launch of the Prostate Vanguard, an awareness campaign to ... replace multiple rectal needle biopsies of the prostate. ... of the prostate gland through the rectum. Multi-parametric MRI ... for diagnosing clinically-significant prostate cancer (CSPC). Men need ...
(Date:9/17/2014)... 2014 Bronstein, Gewirtz & Grossman, LLC is ... securities of PDL BioPharma, Inc. ("PDL BioPharma" or the ... are advised to contact Peretz Bronstein or ... info@bgandg.com or 212-697-6484. The investigation ... executives violated federal securities laws. On September ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... part of the eighth annual DVT (deep-vein thrombosis) Awareness Month, ... of DVT and its risk factors among patients with co-morbid ... respiratory and obesity patients.   DVT remains the ... deaths may be due to PE (pulmonary embolism).(1)  This is ...
... Ill., March 9, 2011 Hospira, Inc. (NYSE: ... announced U.S. Food and Drug Administration (FDA) approval of docetaxel. ... Hospira expects to launch the product later this month. ... variety of cancers. In 2010, U.S. sales of Taxotere were ...
Cached Medicine Technology:Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 2Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 3Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 4Hospira Announces U.S. Approval of Generic Docetaxel 2
(Date:9/17/2014)... that most 18-month-olds learn an average of two to ... about how children process information to learn new words ... new study, a University of Missouri researcher has found ... a limit exists as to how many words they ... enhance their children,s vocabularies and assist speech-language professionals in ...
(Date:9/17/2014)... In a country where 77% of inhabitants ... basis, how can Americans find healthy and fulfilling ways ... Challenge , a 5-day interactive journey to putting stress ... From September 29th – October 3rd, the Hyland’s Stress ... specific topics that promote natural solutions for managing stress. ...
(Date:9/17/2014)... By Kathleen Doheny ... -- Sixteen major food and beverage companies have made good ... a new report finds. The companies, acting together through ... calories from the market between 2007 and 2012 and 1.5 ... calories. "The 16 companies collectively met their pledge and ...
(Date:9/17/2014)... 2014 People with bipolar disorder who do yoga believe ... survey study in the September Journal of Psychiatric ... Lippincott Williams & Wilkins , a part of Wolters ... believe that yoga has had a significant positive impact on ... Uebelacker of Butler Hospital and Brown University, Providence, R.I., and ...
(Date:9/17/2014)... September 17, 2014 For over a ... of MadgeTech data logging products to industries in Greece ... and the development of management systems for certification and ... quality, and technical support. , MadgeTech Inc. is ... internationally. “We are very pleased to see the success ...
Breaking Medicine News(10 mins):Health News:Babies learn words differently as they age, researcher finds 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3Health News:Yoga may help people with bipolar disorder, reports Journal of Psychiatric Practice 2Health News:Yoga may help people with bipolar disorder, reports Journal of Psychiatric Practice 3Health News:Main Solutions Now Distributing MadgeTech Data Loggers in Bulgaria 2
... 2012 Updated guidelines on nutrition and physical activity ... stress the importance of creating social and physical ... updated recommendations for individual choices regarding diet and ... occur within a community context that can either ...
... Mary, University of London suggests that omega-3 fatty acids, which ... nerves from injury and help them to regenerate. When ... experience pain, weakness and muscle paralysis which can leave them ... published this week in the Journal of Neuroscience *, ...
... HealthDay Reporter , TUESDAY, Jan. 10 (HealthDay News) -- ... to trigger declines in lung function that could lead to ... you down that road toward breathlessness, but low to moderate ... But there were limits to the study. For example, ...
... TUESDAY, Jan. 10 (HealthDay News) -- Children with autism have ... seen in kids who do not have the disorder, researchers ... in the online journal mBio , researchers from the ... York City suggested that this finding could help explain the ...
... , TUESDAY, Jan. 10 (HealthDay News) -- People with dementia ... who don,t have any impairment in their brain function, a ... the hospitalizations that occur in people with dementia are for ... study shows. "Hospital admissions for all causes and ...
... Jan. 10 (HealthDay News) -- Heart attack patients whose blood ... to die than those with levels of the mineral below ... current recommendations for potassium levels in heart attack patients. ... admitted to 67 U.S. hospitals between 2000 and 2008. Of ...
Cached Medicine News:Health News:Updated American Cancer Society nutrition guidelines stress need for supportive environment 2Health News:Updated American Cancer Society nutrition guidelines stress need for supportive environment 3Health News:Omega-3 fatty acids could prevent and treat nerve damage, research suggests 2Health News:Occasional Pot Smoking Won't Harm Lungs: Study 2Health News:Occasional Pot Smoking Won't Harm Lungs: Study 3Health News:Autism Gastro Problems May Be Linked to Gut Bacteria 2Health News:Dementia May Lead to Avoidable Hospitalizations 2Health News:Dementia May Lead to Avoidable Hospitalizations 3Health News:Study Challenges Potassium Guidelines for Heart Attack Patients 2
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... The Guidant Flextend lead ... pace/sense lead with an ... extendable/retractable helix design offers ... for permanent implantation in ...
... The PY series leads are ... leads for stimulation of either the ... active fixation screw can be extended ... pin. The lead tip contains an ...
Used with permanent pacing leads....
Medicine Products: